Clinical Trials
42 trialsTissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
RAINFOL-01
Genmab
BASECAMP-1
A2 Biotherapeutics Inc.
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
National Institutes of Health Clinical Center (CC)
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
EVEREST-2
A2 Biotherapeutics Inc.
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
National Institutes of Health Clinical Center (CC)
iCaRe2
University of Nebraska
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Dana-Farber Cancer Institute
TEADCO
Orion Corporation, Orion Pharma
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
eVOLVE-Meso
AstraZeneca
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
ANTARES
Instituto do Cancer do Estado de São Paulo
STEALTH-001
KaliVir Immunotherapeutics
DUAL-MESO-NK
Beijing Biotech
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
DuTOC
Dutch Society of Physicians for Pulmonology and Tuberculosis
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
University of Chicago
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Bristol-Myers Squibb
MAGIC-AKI
Brigham and Women's Hospital
Stereotactic Magnetic Resonance Guided Radiation Therapy
Dana-Farber Cancer Institute
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
Brigham and Women's Hospital
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Baylor College of Medicine
Imaging-Meso
Istituto Oncologico Veneto IRCCS
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
PARTNER
Azienda Ospedaliera di Padova
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
FLAT
National and Kapodistrian University of Athens
AtezoMeso
Gruppo Oncologico Italiano di Ricerca Clinica
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
BridGene Biosciences Inc.
New Preclinical and Clinical Approaches to Mesothelioma
IRCCS Ospedale San Raffaele
EXTRA-Meso (EXercise TheRApy in Mesothelioma) Feasibility
NHS Greater Glasgow and Clyde
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
A&G Pharmaceutical Inc.
PSM
Oslo University Hospital